PubRank

Scott Bowden

Author PubWeight™ 49.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004 3.19
2 Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010 2.61
3 Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010 2.02
4 Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol 2009 1.67
5 A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology 2008 1.52
6 Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol 2002 1.45
7 BK virus-associated progressive multifocal leukoencephalopathy. Med J Aust 2013 1.41
8 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2007 1.28
9 Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002 1.28
10 Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005 1.28
11 Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003 1.21
12 Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther 2007 1.08
13 Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs. PLoS One 2012 1.07
14 Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. Gastroenterology 2011 1.03
15 Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS 2009 1.01
16 Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen. J Virol 2010 0.97
17 Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 2007 0.95
18 Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis 2013 0.93
19 Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease. J Virol 2011 0.92
20 Hepatitis B surface antigen quantification: not what it seems on the surface. Hepatology 2012 0.89
21 Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. J Clin Microbiol 2004 0.88
22 Change in hepatitis C virus genotype in injecting drug users. J Med Virol 2004 0.86
23 Indications of immune protection from hepatitis C infection. J Urban Health 2004 0.86
24 Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood 2005 0.86
25 Drug resistance in antiviral therapy. Clin Liver Dis 2010 0.84
26 High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One 2013 0.83
27 Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antivir Ther 2010 0.83
28 Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. J Gastroenterol Hepatol 2003 0.83
29 Stability of hepatitis C virus, HIV, and hepatitis B virus nucleic acids in plasma samples after long-term storage at -20°C and -70°C. J Clin Microbiol 2011 0.82
30 Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology 2009 0.82
31 Immunosuppression increases latent infection of brain by JC polyomavirus. Pathology 2011 0.81
32 Advances in the molecular diagnosis of hepatitis B infection: providing insight into the next generation of disease. Semin Liver Dis 2013 0.81
33 Decreased viral load and symptoms of polyomavirus-associated chronic interstitial cystitis after intravesical cidofovir treatment. Clin Infect Dis 2009 0.81
34 A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther 2006 0.80
35 Downregulation of HLA class II molecules by G1896A pre-core mutation in chronic hepatitis B virus infection. Viral Immunol 2009 0.80
36 Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals. PLoS One 2013 0.79
37 Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology 2004 0.79
38 Beyond injecting drug use: investigation of a Victorian cluster of hepatitis C among HIV-infected men who have sex with men. Med J Aust 2013 0.78
39 Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints. Gastroenterology 2002 0.78
40 Characterisation of single nucleotide polymorphisms in the genome of JC polyomavirus using MALDI TOF mass spectrometry. J Virol Methods 2009 0.78
41 Use of cidofovir in polyomavirus BK viral nephropathy in two renal allograft recipients. Nephrology (Carlton) 2003 0.78
42 TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus. Immunol Cell Biol 2009 0.77
43 Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin. J Clin Virol 2007 0.77
44 Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy. J Clin Microbiol 2006 0.76
45 A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients. Antivir Ther 2005 0.76
46 Respiratory epithelium: an unlikely reservoir for latent human polyomavirus infection but a likely portal of entry. Transplantation 2010 0.75
47 Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. AIDS 2016 0.75
48 Investigation of infection control practices and knowledge of hepatitis C among body-piercing practitioners. Am J Infect Control 2003 0.75
49 Failure of lamivudine to reverse hepatitis B virus-associated changes in ERK, Akt and cell cycle regulatory proteins. Antivir Ther 2008 0.75